To include your compound in the COVID-19 Resource Center, submit it here.

Increasing Homology

Why Deerfield wanted to increase its stake in gene therapy/editing play Homology

Deerfield Management decided to put more capital into Homology Medicines Inc. based on faith in the new management team’s ability to turn an AAV vector platform into gene therapy and gene editing products.

On Aug. 1, Homology raised $83.5 million in

Read the full 414 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers